Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0522213468
Wed, 20.04.2022
Achiko AG
Achiko AG Signs Major Marketing and Sales Agreement with the World's Largest Islamic Association for its AptameX Covid-19 rapid test
Signed major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta, for the use of Covid-19 test AptameX in general assemblies and activities. Located primarily in Indonesia, Nahdlatul Ulama is the world's larges [ … ]
Wed, 20.04.2022
Achiko AG
Achiko secures up to CHF12m equity and debt financing lines with RiverFort over 3 years
Zurich, 20 April 2022: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (SIX: ACHI; OTCQB:
ACHKF; ISIN CH0522213468) ("Achiko", the "Company") announces the completion of an Equity Subscription Agreement ("ESS") with the institutional investor RiverFort G [ … ]
Thu, 03.03.2022
Achiko AG
Achiko AG Production and Sales Update
- Unique chemistry with DNA Aptamers Completing pre-sales validation testing
- Completing pre-sales validation testing in Indonesia
Zurich, 3 March 2022: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) ("Achiko", the "Company") today announced an update [ … ]
Mon, 14.02.2022
Achiko AG
Achiko AG Research Paper and Commercialisation Update
- Calibration study results now available in draft paper on medRxiv, a preprint platform for health sciences, as "DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit of Saliva Samples for SARS-CoV-2 Virus Linked to Mobile Phone Application"
- AptameX is the world's first scale appl [ … ]
Thu, 27.01.2022
Achiko AG
Achiko AG strengthens senior team with appointment of Head of Corporate Development
- Achiko AG appoints David Hodge to the role of Head of Corporate Development in Switzerland
- David Hodge will oversee Corporate Affairs, and Strategic and Corporate Development
- Board Director Christophe Laurent to retire at month end
Zurich, 27 January 2022 [ … ]
Mon, 17.01.2022
Achiko AG
EQS-News: Achiko AG
/ Key word(s): Miscellaneous
Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology
17.01.2022 / 14:08
Achiko AG Announces Feature Article on How We Get Back to Normal with its AptameXTM Covid-19 Rapid Test Technology
Zurich, 17 January 2022- Achiko [ … ]
Fri, 14.01.2022
Achiko AG
Achiko AG Reports Breakthrough Calibration Results for AptameX Covid-19 Rapid Test Technology
- AptameX(TM) Covid-19 rapid calibration successfully classified 100% of results indicating a likely > 97% Sensitivity and > 97% Specificity result in the first-generation test kits.
- Results were demonstrable both at CT values under 25, and betwe [ … ]
Fri, 31.12.2021
Achiko AG
Achiko AG completing CHF4.85m financing and changes to senior team
- Completing CHF 4.85 million placement from August 2021
- Board Director Christophe Laurent to retire
- Appoints Adam O'Keeffe as ad interim Chief Financial Officer
Zurich, 31 December 2021: Ad hoc announcement pursuant to Art. 53 LR - Achiko AG (OTCQB: ACHKF; SIX: ACHI; ISIN [ … ]
Thu, 23.12.2021
Achiko AG
EQS-News: Achiko AG
/ Key word(s): Miscellaneous
Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution
23.12.2021 / 06:45
Achiko AG looks back at pivotal year and reaffirms commitment to provide affordable and accurate Covid-19 testing solution
- 2021 was a pi [ … ]
Mon, 20.12.2021
Achiko AG
Achiko AG's Shares Begin Trading on the OTCQB Market
Company provides novel solution for Covid-19 testing gap with AptameX(TM), its highly effective and low-cost DNA aptamer-based technology for the detection of Covid-19 and its variants. AptameX represents the first massive use of DNA aptamers at scale versus classical antigenic approaches to rap [ … ]